Tiziana Life Sciences Acquires a Nanoparticle-Based Formulation Technology for Controlled Delivery of Actinomycin D for Treatment of Myelodysplastic syndrome and Acute Myeloid Leukemia
About Tiziana Life Sciences plc
- NASDAQ: $TLSA
- Notified: $2.87
- 14:18 EDT
